What is AltrixBio?
AltrixBio is a biotechnology firm focused on pioneering the first non-systemic, oral therapy designed to mimic the metabolic outcomes of bariatric surgery. The company's lead candidate, LuCI, is built upon a well-established compound and is supported by robust preclinical data. This scalable platform is strategically positioned to address significant health challenges including type 2 diabetes and obesity, with potential applications extending to other metabolic conditions.
How much funding has AltrixBio raised?
AltrixBio has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2025): $5M, investors not publicly disclosed
What's next for AltrixBio?
The substantial enterprise-level funding indicates AltrixBio is poised for significant expansion and clinical development. This strategic investment will likely accelerate the progression of LuCI through clinical trials, aiming to validate its efficacy and safety profile. The company's focus on a non-systemic, oral approach represents a novel therapeutic strategy, and continued investment will be crucial for navigating regulatory pathways and preparing for potential commercialization, further solidifying its position in the metabolic disease market.
See full AltrixBio company page
